Levi & Korsinsky informs Geron Corporation investors of class action lawsuit

Levi & Korsinsky have informed investors of Geron Corporation about a class action lawsuit and upcoming deadline. The deadline is approaching for investors to participate in the lawsuit against Geron Corporation. The lawsuit involves allegations of securities fraud. Investors who bought shares in Gern between March 19, 2018, and September 26, 2018, are eligible to participate in the class action.

The class action lawsuit revolves around claims made by Geron Corporation regarding the safety and efficacy of imetelstat, their cancer treatment drug. The lawsuit alleges that Geron made false and misleading statements about the drug’s prospects to inflate the value of its stock. When the truth about the drug’s efficacy came to light, the stock price plummeted, causing financial harm to investors.

Investors who suffered financial losses due to purchasing shares of Geron during the specified time frame may be entitled to participate in the class action lawsuit. To do so, they must take action before the impending deadline. By joining the lawsuit, investors can seek to recover some of the losses they incurred as a result of Geron’s alleged securities fraud.

The class action lawsuit against Geron Corporation highlights the importance of transparency and accuracy in the pharmaceutical industry. Investors rely on accurate information to make informed decisions about where to put their money. When companies misrepresent the facts, investors can suffer significant financial losses.

If you bought shares of Geron Corporation between March 19, 2018, and September 26, 2018, and suffered financial losses as a result, you may be eligible to participate in the class action lawsuit. The deadline for joining the lawsuit is fast approaching, so investors should act promptly to protect their rights and seek potential compensation for their losses.

In conclusion, investors who purchased shares of Geron Corporation during the specified time frame may be entitled to participate in a class action lawsuit against the company. The lawsuit alleges securities fraud related to claims made about the efficacy of Geron’s cancer treatment drug. Investors who suffered financial losses as a result of the alleged fraud should take action before the deadline to seek potential compensation for their losses.